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ABSTRACT  
The adoption and use of biological marker also known as biomarkers in clinical studies and management of disease conditions spans over 40 
years. Biological marker are measurable biochemical or molecular alterations that can be adopted as indicator of normal biological or 
responses to the action of pathogen or pharmacological responses to a therapeutic intervention. Molecules, macro and micro molecules,  
metabolites, and chemical compounds from the body adopted for use in predicting and monitoring health outcomes are constant from 
individual to another which qualify them as standard biomarker parameters. Use of biological markers spans clinical screening of an underlying 
cause of disease, prognosis, predisposition to a disease condition and predicting outcomes of treatment. In the environment, biological markers 
can be applied to determine the effects of xenobiotic chemicals and reaction effect on living cell. A good marker while being specific, should be 
easy to measure, cheap, provide correct measurement and outcomes. The objective of this review paper is highlight the different types of 
biological markers and areas where they are applicable.  
 
Article Info: Received 21 March 2020;     Review Completed 27May 2020;     Accepted 05 June 2020;     Available online 15 June 2020 
Cite this article as: 
Orole OO, Nevkaa DN, Terna FC, Olokun AL, LAMINI JN, Salami OM, Biological Markers as a Novel Approach in Clinical 
Diagnosis and Management of Diseases, Journal of Drug Delivery and Therapeutics. 2020; 10(3-s):341-347 
http://dx.doi.org/10.22270/jddt.v10i3-s.4105                                                                                                          
*Address for Correspondence:  




Biological markers are quantifiable indicators or assessors 
of biological states or conditions. It is also referred to as 
biomarkers. The term biological markers have been in 
existence and use since 1970s, mostly in clinical research on 
cancer and cardiovascular disease. Biomarker is a measure 
used to define a pathologic or biologic process and in 
monitoring progression of a therapy (NIH, 2001). It works 
by changing progression based on degree of intervention as 
the disease condition progresses. Biomarkers can measure 
level of disease through diagnosis or the efficiency of 
therapy or treatment. An ideal biomarker is non-invasive, 
and allows measurements to be repeated. It should be 
simple, quantitative, and accurate in relation to the 
biological process in question while, progression or such 
measurement should be predictive and meaningfully aid 
interpretation of the biological scenario. Example of a non-
chemical biomarkers include the size of cysts in polycystic 
kidney disease, renal pelvic diameter in prenatal 
ultrasounds and statistics showing 24 h ambulatory blood 
pressure recording.  
While a risk factor can be independent of a biological 
process, biomarker is a dynamic viral load and CD4 cell 
counts to access disease progression of HIV induced 
immunosuppression and to predict outcomes like 
opportunistic infections and death, the concentration of 
blood pressure and serum cholesterol to check for disease 
progress of vascular injury/atherosclerosis and may serve to 
predict events leading to cardiovascular and 
cerebrovascular diseases; the serum levels of C3 and C4 
complement to monitor disease processes that involve 
complement consumption resulting from immune complex 
activation and may be a prediction for immune-mediated 
(inflammatory) tissue injury. 
Biomarkers accesses factors like rate of heart beat, blood 
pressure, temperature, pathological processes like disease 
stage, or pharmacologic responses to a therapeutic 
intervention (Albert, 2011). Biomarkers are also described 
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as measurable substances, structure or process quantifying 
the relationship between a biological factor and a risk factor. 
Biomarkers measures biological substances such as 
macromolecules derived from blood (DNA, RNA, proteins, 
lipids), body fluids such as urine, stool, sputum or tissues so 
as to be able to access a person well-being and so be able to 
plan the best care (Calzone, 2012; IOM, 2010; Allegra et al., 
2009). Biological markers’ application in medical research 
and other sciences enables rapid performance of clinical 
studies, predict disease risks, monitor disease status, and 
give relevant information that could lead to interventions 
that can save lives (Albert, 2011).  
Nature of Biomarkers 
Biomarkers can be simple or complex in nature. Simple 
biomarkers include glucose, steroids, lipids, etc. while 
complex biomarkers include T cells, auto-antibodies, etc. 
According to Stimbul and Tavel (2010) biomarkers can be 
any of the following; a piece of DNA or RNA, any protein, any 
metabolite, and protein interactions. Sahu et al. (2011) and 
Hulker (1991) described an ideal biomarker to be 
characterized as follows; 
 It should be specific for a particular disease condition 
and be able to define different physiological states  
 It should give accurate measurement method  
 Safe and easy to measure. 
 Rapid so as to enable faster diagnosis. 
 Cheap and affordable. 
 It should be efficient, providing dependable outcomes. 
 Consistent between different ethnic groups and 
genders. 
Biomarkers are present in tissue, blood, lymph, and in fluids 
like breast milk, urine, sputum, and stool, premalignant or 
malignant cancer cells, and in body secretions and can be 
analyzed in them (IOM, 2010). 
Types of Biomarkers 
A) Biological markers can be classified based on their 
characteristics as follows 
i) Imaging biomarkers 
An imaging biomarker is an indicator of the integrity of 
tissues in the form of an image. It quantifies structural and 
functional parameters in biological entities. They are non-
molecular in nature and non-biased in obtaining medical 
images extracted after applying computational models and 
signal processing to images. An imaging biomarker is both 
qualitative and quantitative biological parameter, non-
invasive, producing results that are intuitive and 
multidimensional in nature. In lung cancer, simple lesion in 
the lung to include the size and other characteristics are 
biomarkers detected by X-ray, CT, or MRI. 
ii) Molecular biomarkers 
Molecular biomarkers measures biological samples with 
biophysical properties. Bodily samples like fluid, tissues or 
cell components to include nucleic acids can be adopted as 
molecular markers. These quantify gene mutations or 
polymorphisms, gene expression, macro and micro 
molecules. 
B) Biomarkers are also classified according to their 
application as follows: 
i) Predisposition Biomarkers 
A predisposition or susceptibility biomarker is an indicator 
measuring chances of coming down with a disease condition 
from a medical point of view is yet to have such a medical 
condition. It is also referred to as risk biomarkers. The 
biomarkers shows or estimates and determines the risk 
associated with coming down with or not developing a 
disease condition, and the risk factor that may increase or 
decrease the individual risk. Examples of predisposition 
include genetic biomarker indicating whether one has 
increased chance of coming down with cancer at a later 
stage in life, elevated LDL biomarker which indicate 
increased risk of developing coronary artery disease, and 
BRCA1/2 mutation which evaluates the likelihood of breast 
and ovarian cancers. Such biomarkers quantifies the effect 
lifestyle, nutritional, and other interventions have in 
predisposing people to disease condition. Biological markers 
measuring inert response rate to a toxic substance by an 
organism could be termed as Biomarkers of susceptibility 
(Strimbu and Tavel, 2010). This involves the genetic 
predisposition of an individual as it affects susceptibility to 
chemical materials.  
External factors, such as age, diet and health status, can also 
influence the susceptibility of an individual during exposure 
to chemicals (IOM, 2010). The biomarker can also be 
adopted to identifying people who need more monitoring 
and better management in their therapies (Struewing, 
1997). The value of a predisposition biomarker is dependent 
on available therapy adopted in the management of such 
clinical cases. Other examples of the predisposition 
biomarker are Factor V Leiden (for those predisposed to 
developing deep vein thrombosis) (Kujovich, 2011), 
Apolipoprotein E (APOE) gene variations (in people likely to 
develop Alzheimer’s disease) (Genin et al., 2011) and C-
reactive protein (CRP) level (in individuals with 
predisposition to coronary disease) (Greenland et al., 2010) 
ii) Diagnostic Biomarkers 
Diagnostic biological markers predict without measuring the 
severity the disease type or subtype a particular individual 
has (Zauber et al., 2012). The biomarker also identifies 
individuals at high risk levels for disease as a result of the 
specificity of their genetic make-up (Calzone, 2012). As a 
result of the importance of accurate diagnosis of disease, 
critical determination of a patient condition requiring 
attention can be better managed using these biomarkers 
more so that many diseases have subtypes with markedly 
different reaction to a specific treatment (Best, 2016). 
A diagnostic biological marker detects the process leading to 
a disease condition faster radiography or imaging 
appliances. Examples of diagnostic biomarker are Sweat 
chloride used to confirm cystic fibrosis (Farrell et al., 2008), 
Ejection fraction can be adopted in individuals with heart 
challenges to identify patients with a subset of disease 
(those with low ejection fraction or preserved ejection 
fraction) (Yancy et al., 2013) and gene expression profiling 
used to segregate patients with diffuse large B-cell 
lymphoma into subgroups with different tumor cell of origin 
signatures (Scott et al., 2014). 
iii) Prognostic Biomarkers 
A prognostic biomarker accesses the progression of a 
disease condition and the rate of such progression. It aid in 
determining the success of medical response by providing 
relevant data of a patient health outcome (e.g. disease 
recurrence) irrespective of the treatment and shows if 
someone is at risk of developing disease (Ruberg and Shen, 
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2015). Konstantinos et al. (2018) describes prognostic 
biomarkers as indicators that suggest the likelihood of 
occurrence of a clinical condition in an individual not on 
treatment plan, while others describe them as parameters 
that help to determine or calculate the probability of disease 
recurrence or progression. 
Oncotype Dx is a prognostic biomarker that determines the 
likelihood that breast cancer will develop again in an 
individual that has already been diagnosed and on initial 
treatment. Examples such as PSA level (prostate cancer 
prognosis) and PIK3CA mutation status is prognostic in 
women with HER2-positive metastatic breast cancer 
undergoing first-line therapy (Baselga et al., 2014).   
iv) Predictive Biomarkers  
Predictive biological markers are employed to give 
information on the likely outcome of a therapy. Prediction 
biomarkers can highlight among patients, individuals that 
are likely to respond positively to a choice therapy 
(Konstantinos et al., 2018). With the help of predictive 
biomarkers, it is possible to administer a particular therapy 
to patients with improved chances of treatment success. The 
difference between prognostic marker and predictive 
biomarker is prognostic markers measures the total 
outcome of a disease condition while predictive markers on 
the other hand on measure the outcome or response to a 
therapeutic activity. A predictive biomarker only provide 
information on the effect of a therapy adopted (Oldenhuis et 
al., 2008), while prognostic biomarker provides information 
on the likely patient health outcome (e.g. disease 
recurrence) irrespective of the treatment.  
v) Pharmacogenetics biomarkers 
Pharmacogenetics biomarkers help in determining the 
pharmacological response to a drug or treatment line (Wang 
et al., 2011). According to Weinshilboum (2003), in many 
diseases, inherited germ line DNA sequence variants, known 
as single nucleotide polymorphisms (SNPs), may determine 
individual differences in drug distribution within the body, 
metabolism, or effect on target tissues. These markers 
predict individual’s response to the activities of drugs (Wang 
et al., 2011). 
Drug activity biomarkers may be further divided According 
to Wang et al. (2011) into:- 
1. Efficacy biomarkers – indicating the therapeutic effects 
of a drug 
2. Mechanism biomarkers – giving information about the 
mechanism of action of a drug 
3. Toxicity biomarkers – indicating the toxicological 
effects of a drug 
vi) Omics-based biomarkers 
Single analyte biomarkers have been generated and studied 
over the years because of a preconceived biological 
association between them and the associated disease 
(Hammond et al., 2010). An example is adoption of ER as 
beneficial effect modifier of endocrine therapy (McGuire et 
al., 1975; Hammond et al., 2010).  
vii) Natural history biomarkers 
These are biomarkers that help measure the natural history 
of a disease and correlate over time with known clinical 
indicators (Strimbu and Tavel, 2010). 
viii) Predisposition biomarkers or surrogate endpoint 
biomarkers: 
A surrogate endpoint is expected to predict clinical benefit 
or harm or lack of benefit or harm based on epidemiologic, 
therapeutic, pathophysiologic, or other scientific evidence 
(Biomarkers Definitions Working Group, 2001; IOM, 2010). 
They are helpful in identifying the chances or probability of 
contacting a disease. A surrogate endpoint may provide the 
clinician either increased certainty that an event is already 
occurring or is likely occur. For instance, the rising level of a 
tumor biomarker in the bloodstream of a patient with 
previously established cancer may be an indication of an 
impending relapse, and might guide earlier intervention 
than if the clinician waits for the relapse to be detectable by 
other means (Biomarkers Definitions Working Group, 2001; 
IOM, 2010). 
ix) Screening Biomarkers and monitoring biomarkers 
Screening Biomarkers and monitoring biomarkers are 
helpful in screening for people infected by a disease, while 
Monitoring biomarkers are useful for monitoring previously 
effected individuals who had been declared disease free, to 
detect an event earlier than what might be possible with 
standard clinical approaches (Sahu et al., 2011). Recurrence 
monitoring biomarkers are beneficial in identifying disease 
recurrence. 
C) Biomarkers can be classified according to its function 
as follows 
1. Biomarkers of Exposure 
Biomarkers of exposure quantifies externally released 
substances or its resulting metabolites or the products 
formed through reactions between a toxic compound and 
living cells and measured in a compartment within an 
organism (WHO, 2001). In this context, chemical 
concentrations in food, water and air, selected 
environmental concentrations (e.g., occupational or 
residential settings) as well as measures of the actual 
exposures experienced by the individual or population can 
be measured. Toxicity is produced in specific sites in the 
body at concentrations and for duration at which the toxic 
effect become manifest. To this end, labelling a the toxicity of 
chemical agent in a diseased person requires understanding 
of the type of effects and the dose at which the effects are 
produced, understanding the duration and frequency of 
exposure and level of susceptibility of the concerned 
individual (WHO, 1991). According to WHO (2001), 
biomarkers of exposure reveal the distribution of an 
exogenous compound or its metabolite in the organism.  
2 Biomarkers of Effect 
Hammond et al. (2010) described biomarkers of effect as 
“measurable biochemical, physiological, behavioral or other 
alterations within an organism that, depending upon the 
magnitude, can be recognized as associated with an 
established or possible health impairment or disease”. 
Examples include the expression of ER and HER2 for 
therapies in breast cancer, K-ras mutations for antibody 
therapy, and ALK (anaplastic lymphoma kinase) mutations 
for therapies in lung cancer (Hammond et al., 2010; Shaw et 
al., 2010; Allegra et al., 2009; Wolff et al., 2007). Examples of 
biomarkers of effect include: 
a)  Hematological biomarkers 
Nielsen et al. (1992) reported that inhibition of the enzymes 
in the haem synthesis pathway such as ferrochelatase, 
levulinate and dehydratase has been used as a marker of 
effect of exposure to lead. 
b)  Nephrotoxicity biomarkers 
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Different types of indicators used as biomarkers of renal 
damage, have been classified as functional markers (e.g., 
serum creatinine and 82 macroglobulin), urinary proteins 
of low or high molecular weight (e.g., albumin, transferrin, 
retinol- binding globulin, rheumatoid factor, 
immunoglobulin G), cytotoxicity markers (tubular antigens, 
e.g., BBSO, BBA, HFS), enzymes (e.g., N-
acetylglucosaminidase, agalactosidase) in urine, and 
biochemical markers (eicosanoids, e.g., 6-keto PGF2a, PGF2, 
PGF2a and TXB2, fibronectin, kallikrein activity, sialic acid 
and glycosaminoglycans in urine, and red blood cell 
negative charges) (WHO,1991). 
c)  Liver toxicity biomarkers 
An important biomarker used to measure the effects of 
exogenous compounds in the liver is the activities of the 
enzymes aminotransferases (most often aspartate or 
alanine aminotransferase) in the serum (Aberle et al., 
2011). These enzymes are detected when liver cells have 
been damaged and have leaked or emptied their contents. 
Other enzymes that serve as liver toxicity biomarkers 
include 5-nucleotidase, alcohol dehydrogenase, lactate 
dehydrogenase, isocitrate dehydrogenase, leucine 
aminopeptidase, etc. Analysis of specific isoenzymes has 
been used to overcome this lack of specificity, and serum 
activities of enzymes such as alkaline phosphatase and 1- 
glutamyl transpeptidase may also be considered as 
biomarkers of hepatic damage, mostly involving biliary 
excretion (Aberle et al., 2011). 
d)  Immunotoxicity biomarkers 
Elevated levels of specific antibodies, usually of the 
Immunoglobulin E (IgE) type, may indicate existing 
sensitization. However, not all individuals with elevated 
levels are symptomatic and not all symptomatic individuals 
exhibit elevated IgE levels (Wolff, 2007). Patch testing has 
been used traditionally as a biomarker for identification for 
allergic skin reactions (Wolff, 2007). 
According to Albert (2011), the most sensitive biomarker of 
an inflammatory response in the bronchoalveolar region is 
the number of neutrophils in BALF (bronchoalveolar lavage 
fluid). Increase in protein concentrations in BALF indicate 
increased permeability of the alveolar or capillary barrier. 
IOM (2010) stated that Lactate dehydrogenase (LDH) is a 
cytoplasmic enzyme that is found extracellularly only in the 
presence of lysed or damaged cells and it’s a useful 
biomarker of pulmonary toxicity. Similarly Shaw et al. 
(2010) reported that Beta-glucuronidase or similar 
lysosomal hydrolytic enzymes are excellent markers for the 
toxicity of inhaled particles.  
e) Reproductive and developmental toxicity biomarkers 
Physiological indicators of impaired testicular function or 
sperm number or characteristics have been identified as 
biomarkers for the male reproductive system (Strimbu and 
Tavel, 2010). According to Sahu et al. (2011), these markers 
include low birth weight, chromosome anomalies, and 
delayed growth of specific organ systems, mental 
retardation, and subtle behavioural changes. 
f) Neurotoxicity biomarkers   
Owing to the complexities that accompany the functions of 
the nervous system, neurotoxicity biomarkers could range 
from effects of chemicals on neural cellular and molecular 
processes to neurophysiological and neurobehavioural 
measurements of complex functional entities (Calzone, 
2012). According to Hulka (1991), inhibition of plasma and 
erythrocyte acetylcholine esterase (AchE) can be used as a 
marker of exposure to organophosphorus compounds and 
other cholinesterase inhibitors. 
 
3 Burdens of Disease Biomarkers 
Biomarker in this group shows the level of severity of a 
disease by comparing disease state disease to a defined 
accepted standard. While the biomarker accesses the state of 
the disease. Biomarkers of burden of disease can be accessed 
depending on what is being monitored. Extract from the 
synovial fluid can only predict disease level in a single joint, 
while assessment of blood or urine will show disease status 
in all joints.  
4 Biomarkers of Efficacy of intervention  
Efficacy of intervention biomarkers ranges from target 
engagement and pharmacodynamic assays (which assess 
whether the compound is hitting the desired target and is 
obtaining the expectant effects and responses to end-result 
that manifest impact of treatment agent on the disease signs 
and symptoms (Emrani et al., 2008). These biomarkers are 
important in drug development as they influence dose 
selection decisions (Karsdal et al., 2009). 
Applications of Biomarkers 
1. Application to chronic kidney disease:  kidney 
disease has historically been described in terms of 
clinical observations that have been supplemented by 
the measurements of chemicals in blood or urine 
which shows differing levels of organ function. There 
has been a recent increase of interest in the use of 
biomarkers as tools for clinical research in nephrology. 
Examples of classical biomarkers in chronic kidney 
disease (CKD) 
Proteinuria: For many years quantitative proteinuria or 
albuminuria has been a classical biomarker accounting for 
renal injury and also serving as a predictor for progress in 
CKD. The prognostic use of proteinuria shows and predicts 
later development of nephropathy in type 1 diabetes 
individuals (Viberti et al., 1982, Mogensen and Christensen 
1984). Proteinuria is predictive of nondiabetic CKD 
progression (Hunsicker et al., 1997, Ruggenenti et al., 1998). 
Urinary albumin excretion predicts the progress of risk in 
CKD (Eknoyan et al., 2003). Firstly it is a hybrid marker 
which may show acute or chronic injury or in many cases a 
combination of both. Interpreting proteinuria properly 
needs attention to the clinical context and there may be a 
requirement of serial determination. An example is about 
one in three of paediatric type 1 diabetes with 
microalbuminuria return to normoalbuminuria after 3-6 
years of follow up (Rudberg and Dahlquist 1996, Gorman et 
al., 1999). Other parameters adopted as biomarkers are 
nephranuria to predict injury in diabetic nephropathy 
(Patari et al., 2003), urinary exosomes to probe the tubule 
compartment of the kidney (Zhou et al., 2006). 
Cyturia: Urine will continue to be rated above others as a 
source of biomarker in CKD because its collection is non-
invasive and it is readily available and there is also an 
intimate connection of urine proteins to kidney processes. 
Hara et al., depicted the presence of podocytes in the 
sediments of urine of children with a variety of glomerular 
disease (Hara et al., 1998). More recently it has been shown 
that podocytes are shed in varying amounts into the urine by 
both healthy and diseased patients, therefore podocyturia 
may be quantifiable to urinary creatinine as a ratio, with the 
ratio differing in active and quiescent disease (Vogelmann et 
al., 2003). 
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The presence of podocytes in urine is an indication of 
glomerular injury; podocytes are regarded as post-mitotic 
cells that contribute to glomerular tuft stability (Kriz and 
Lemley 1999). It is expected that the presence of podocytes 
in urine correlates with their loss from the glomerulus. 
Podocytes presence in urine to predict glomerular sclerosis 
and kidney function loss (Lemeley et al., 2002, Wharram et 
al., 2005). The excretion rates of nephrin and podocin mRNA 
have been correlated with loss of renal function 
subsequently (Szeto et al., 2005). 
2. Biomarkers in nutritional epidemiology 
Research showed that the observed international differences 
in the occurrence of many chronic diseases such as cancer 
are mostly due to environmental factors such as diet. Many 
diet factors contribute to the cause or prevention of disease; 
these factors range from traditional nutrients, to foods to 
phytochemicals and contaminants. However the cause of the 
disease and the diet requires individual risk exposure 
associations. It is stated by Beaton et al. (1997) that there 
will always be dietary assessment errors. However the 
challenge is usually to estimate, understand and make use of 
the error structure during analysis. To be able to do this 
effectively has become possible with the presence of 
biological markers in biological specimen such as blood, 
urine, and hair which is able to reflect sufficient intake as 
closely as possible to act as objective indices of true intake. 
Biomarkers may also be used to account for accuracy of 
dietary assessment methods. Few biomarkers of dietary 
intake will be illustrated below 
Fatty acids: the fatty acid composition of subcutaneous 
adipose tissue can be related to estimates of fatty acid intake 
(Plakke et al., 1983), pentadecanoic acid  is a marker for 
predicting dietary fat within mammalian cells (Wolk et al., 
1998). There has also been a considerable association 
between the total amount of milk product fats produced by a 
7 day record and serum cholesterol esters (Smedman et al., 
1999). 
24 hour urine nitrogen: this is the most popular biological 
marker, where subject dietary intake is kept constant over 
elongated periods of time to present a fairly correlated 
relationship between daily nitrogen intake and daily 
nitrogen excretion. The use of this method is dependent on 
assuming that individuals are in nitrogen balance with no 
accumulation as a result of growth or repair of lost muscle 
tissue or loss due to injury, slimming or starvation. The 
obvious accuracy of 24 hour nitrogen as a biological marker 
has paved way for assuming that it can be used to validate 
protein intake from various dietary survey methods 
(Issakson 1980). 24 hour urine has been found to correlate 
with diet history estimate of protein intake by Van Staveren 
et al., 1985. 
24 hour urine potassium: urine is the main route of 
excretion of potassium in healthy individuals. Excretion of 
potassium in the feces constitutes from 5 to 13 mmol per 
day in Western populations, or 11–15% of the dietary intake 
(Bingham et al., 1989). Studies that have obtained at least 
eight 24-hour urine collections, validated for their 
completeness, have shown correlations of at least 0.7 
between calculated intake and excretion (Bingham et al., 
1997). Potassium has an advantage as a biomarker of diet 
because a greater variety of foods are good sources of 
potassium than those containing protein, for example 
vegetables and fruits. 
 
 
3. Clinical Applications of glycobiomarkers  
Glycans are characterized uniquely and vary significantly 
from proteins and nucleic acids in terms of structure, 
function, and biosynthesis. The development and 
progression of disease is often times related to variations in 
glycosylation on tissue proteins and or blood proteins. 
Glycans released from tissue or blood proteins are known to 
be an important source of biomarkers. Glycosylation can be 
adopted as markers for congenital disorders of glycosylation 
(CDG) (Eklund and Freeze, 2006), ovarian cancers 
(Leiserowitz et al., 2007), rheumatoid arthritis and systemic 
lupus erythematosus (Wuhrer, 2007), IgA nephropathy. 
Conclusion 
Biomarkers greatly have the advantage of advancing 
diagnosis and management of disease conditions while it can 
also be applied to elucidate xenobiotic build up in the 
environment. Successful management of these conditions is 
dependent on early detection which a biological marker 
provides. Biomarkers still have the challenge of similar 
response to different body fluid or organ sampled. To this 
end development of a multi-platform approach is 
recommended while further research studies should be 
explored. 
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